Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Fosun Pharmaceutical’s subsidiary, Hebei Wanbang Folon Pharmaceutical, has successfully had its drug registration application for Tao Hong Si Wu Granules accepted by the National Medical Products Administration. This innovative traditional Chinese medicine is designed to address symptoms related to blood deficiency and circulation, such as irregular menstruation and abdominal pain. The acceptance marks a significant step forward in expanding Fosun Pharma’s product offerings in the traditional medicine market.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.